



Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

29 January 2026 - Allergy Therapeutics plc (AIM:AGY), the fully commercial biotechnology company specialising in allergy immunotherapies, announces that all resolutions proposed at the 2026 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.

Resolutions 1 to 10 (inclusive), were proposed as ordinary resolutions and resolutions 11 to 13 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.

Resolution	For:	%	Against:	%	Total Votes Cast	% of ISC	Withheld
1. Approval of 2025 Accounts	5,820,380,278	99.99%	755,751	0.01%	5,821,136,029	94.78%	56,047
2. Approval of Directors' Remuneration Report	5,820,138,203	99.99%	836,062	0.01%	5,820,974,265	94.78%	217,811
3. To elect Helge Weiner-Trapness as a Director	5,818,973,760	99.99%	141,507	0.01%	5,819,115,267	94.75%	2,076,809
4. To elect Lawrence Allen Wang as a Director	5,818,962,852	99.99%	130,779	0.01%	5,819,093,631	94.75%	2,098,445
5. To re-elect Tunde Otolana as a Director	5,818,680,380	99.99%	418,353	0.01%	5,819,098,733	94.75%	2,093,343
6. To re-elect Cheryl MacDiarmid as a Director	5,818,939,949	99.99%	157,006	0.01%	5,819,096,955	94.75%	2,095,121
7. To re-elect Peter Jensen O.B.E. as a Director	5,804,855,547	99.76%	14,246,551	0.24%	5,819,102,098	94.75%	2,089,978
8. To re-appoint BDO LLP as auditors of the Company	5,818,732,937	99.99%	126,888	0.01%	5,818,859,825	94.75%	2,332,251
9. To authorise the Directors to agree the auditors' remuneration	5,820,969,519	99.99%	134,889	0.01%	5,821,104,408	94.78%	87,668
10. Authority to allot shares	5,820,919,431	99.99%	179,941	0.01%	5,821,099,372	94.78%	92,704
11. Special Resolution: Subject to the passing of Resolution 10, to authorise the Directors to allot equity securities	5,817,602,998	99.94%	3,509,576	0.06%	5,821,112,574	94.78%	79,502
12. Special Resolution: Subject to the passing of Resolution 10, to authorise the Directors to allot equity securities							

Resolution 10, to authorise the Directors, in addition to any authority granted under Resolution 11, to allot equity securities	5,817,696,087	99.94%	3,419,851	0.06%	5,821,115,938	94.78%	76,138
13. Special Resolution: To amend the Articles of Association	5,818,896,008	99.99%	198,676	0.01%	5,819,094,684	94.75%	2,097,392

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries and branches in nine major European countries and via distribution agreements in an additional four countries. For more information, please see www.allergytherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGAKCBDQBKDBDB